What is OneOme?
OneOme provides comprehensive, end-to-end pharmacogenomics solutions for the healthcare industry. Leveraging its foundation co-founded by Mayo Clinic, the company integrates advanced laboratory testing, sophisticated analytics, and clinical decision support tools. These offerings are designed to enhance patient care by enabling personalized medicine, ultimately aiming to reduce healthcare costs and improve patient outcomes. OneOme's services cater to a global clientele from its headquarters in Minneapolis, MN, serving stakeholders from individual patient testing to population-level data analysis and laboratory software support.
How much funding has OneOme raised?
OneOme has raised a total of $4.3M across 4 funding rounds:
Unspecified
$1M
Private Equity
$530K
Debt
$2.1M
Debt
$611K
Unspecified (2015): $1M, investors not publicly disclosed
Private Equity (2016): $530K, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Debt (2021): $611K featuring PPP
Key Investors in OneOme
PPP
Public-Private Partnership
What's next for OneOme?
With substantial enterprise-level backing and a recent strategic investment, OneOme is well-positioned for accelerated growth. The company's focus on integrating pharmacogenomics into routine patient care, supported by robust analytics and clinical decision support, aligns with the increasing demand for personalized medicine. Future developments are likely to involve expanding its laboratory testing capabilities, enhancing its analytics platform, and forging new partnerships within the healthcare ecosystem to further its mission of improving patient outcomes and optimizing care delivery.
See full OneOme company page
